(BCFE) UBS (Irl) Fund Solutions - Ratings and Ratios
Broad, Commodity, Exposure, ETF, Hedged
Description: BCFE UBS (Irl) Fund Solutions
The UBS (Irl) Fund Solutions plc - Bloomberg Commodity CMCI SF UCITS ETF (hedged to EUR) A-acc is designed to replicate the performance of the UBS Bloomberg BCOM Constant Maturity Commodity Index Total Return, providing investors with broad exposure to the commodities market. This ETF is particularly suited for those seeking to diversify their portfolios by gaining access to a wide range of commodities.
From a technical standpoint, the ETFs price action indicates a slight downturn, as evidenced by its current price of 13.97 being lower than both its 20-day and 50-day Simple Moving Averages (SMA) of 14.08 and 14.14, respectively. However, it remains above its 200-day SMA of 13.67, suggesting a longer-term uptrend. The Average True Range (ATR) of 0.16, or 1.14%, indicates moderate volatility. Given these technical indicators, a potential trading strategy could involve waiting for a breakout above the 52-week high of 14.61, which could signal a continuation of the uptrend.
Fundamentally, the ETF has Assets Under Management (AUM) of 110.80M EUR, indicating a reasonable level of investor interest. The commodities market, to which this ETF provides exposure, is influenced by a variety of factors including supply and demand dynamics, geopolitical events, and macroeconomic trends. The Bloomberg Commodity CMCI SF UCITS ETF offers a diversified commodity exposure, mitigating the risks associated with individual commodity investments.
Forecasting the ETFs performance involves analyzing both technical and fundamental data. Given the current technical indicators and the ETFs position relative to its SMAs, a cautious outlook is warranted. If the ETF can break through its 52-week high, it may signal a strong upward trend. Fundamentally, the commodities market is expected to be influenced by global economic recovery trends, potential supply chain disruptions, and shifts in energy policies. Assuming a moderate economic growth scenario and continued demand for commodities, the ETF could potentially see an increase in value. A forecast based on these considerations suggests a potential target price of 15.00 in the medium term, representing a 7.5% increase from the current price, driven by a combination of technical breakout and favorable fundamental conditions.
Additional Sources for BCFE ETF
BCFE ETF Overview
Market Cap in USD | 131m |
Category | Commodities - Broad Basket |
TER | 0.30% |
IPO / Inception | 2017-05-25 |
BCFE ETF Ratings
Growth Rating | 55.6 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | 4.13 |
Analysts | - |
Fair Price Momentum | 13.69 EUR |
Fair Price DCF | - |
BCFE Dividends
Currently no dividends paidBCFE Growth Ratios
Growth Correlation 3m | 80.1% |
Growth Correlation 12m | 81.5% |
Growth Correlation 5y | 56.7% |
CAGR 5y | 11.48% |
CAGR/Max DD 5y | 0.42 |
Sharpe Ratio 12m | 0.75 |
Alpha | -2.43 |
Beta | 0.345 |
Volatility | 13.30% |
Current Volume | 0.1k |
Average Volume 20d | 0.6k |
As of July 06, 2025, the stock is trading at EUR 14.30 with a total of 132 shares traded.
Over the past week, the price has changed by +0.96%, over one month by +1.14%, over three months by +4.43% and over the past year by +3.90%.
Partly, yes. Based on ValueRay´s Analyses, UBS (Irl) Fund Solutions (XETRA:BCFE) is currently (July 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 55.55 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCFE is around 13.69 EUR . This means that BCFE is currently overvalued and has a potential downside of -4.27%.
UBS (Irl) Fund Solutions has no consensus analysts rating.
According to our own proprietary Forecast Model, BCFE UBS (Irl) Fund Solutions will be worth about 15.1 in July 2026. The stock is currently trading at 14.30. This means that the stock has a potential upside of +5.87%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 15.1 | 5.9% |